Russell LaMontagne

Company: Boston Immune Technologies

Job title: President & Chief Executive Officer

Seminars:

TNFR2 Antagonism in the Tumor Microenvironment 1:30 pm

NFR2 is highly expressed on Tregs in the tumor microenvironment TNFR2 has been identified in multiple mechanism tumors use to escape immune surveillance TNFR2 plays a role in resistance to checkpoint blockade TNFR2 antagonist antibodies have are being tested as monotherapy and combination options in multiple cancersRead more

day: Pre-Conference Day